Research use only
Pepura Labs

Research

TRIUMPH-1 Phase 3 Trial Results: What Researchers Need to Know

August 28, 2026

TRIUMPH-1 Phase 3 Trial Results: What Researchers Need to Know

When Eli Lilly announced topline results from the TRIUMPH-1 clinical trial on May 21, 2026, the metabolic research community had its most data-dense single day in years. A 28.3% mean body weight reduction at 80 weeks with Retatrutide 12 mg weekly, in a 2,339-participant randomized controlled trial, does not just move the needle on anti-obesity pharmacology. It recalibrates the baseline against which all future incretin-class compounds will be measured. For researchers studying receptor pharmacology, incretin signaling, or metabolic disease mechanisms, parsing what TRIUMPH-1 actually measured, and how it measured it, is not optional background reading. It is the primary document.

Table of Contents

What Is TRIUMPH-1 and How Was It Designed?

TRIUMPH-1 (NCT05929066) is a Phase 3, randomized, double-blind, placebo-controlled trial evaluating Retatrutide in adults with obesity or overweight who had at least one weight-related comorbidity. The trial enrolled 2,339 participants and tested three active doses: 4 mg, 9 mg, and 12 mg once weekly, alongside a placebo arm. All participants randomized to Retatrutide began at 2 mg once weekly and escalated in a stepwise fashion every four weeks until reaching the target dose.

The primary treatment period ran to 80 weeks. A prespecified blinded extension enrolled the first 532 participants from participating countries who completed Week 80 on study drug without discontinuation or permanent dose reduction, had a baseline BMI of at least 35 kg/m², and maintained a BMI above 22 at Week 80. This extension extended observation to 104 weeks and was not an add-on protocol but a deliberately prespecified component of the master trial design.

TRIUMPH-1 used an innovative basket trial methodology, which is a design approach borrowed from oncology and applied here to the cardiometabolic space for what is believed to be the first time. The master trial for obesity anchored two sub-trials, called baskets: one evaluating moderate-to-severe obstructive sleep apnea (OSA), and one evaluating knee osteoarthritis pain in participants with obesity. Each basket had its own population, endpoints, and analysis plan, with type I error controlled at alpha = 0.05 split between the overarching weight management study and each basket trial. This structure allowed independent statistical testing of all three components under a single master protocol.

The primary endpoint for the weight management master trial was percent change in body weight from baseline. The OSA basket measured change in Apnea-Hypopnea Index. The knee OA basket measured change in the Western Ontario and McMaster Universities Osteoarthritis Index pain subscale score. Every dose arm met the primary and key secondary endpoints for the obesity component.

Pro tip: When reviewing TRIUMPH-1 data in a research context, distinguish carefully between the 80-week primary endpoint results and the 104-week extension results. The extension cohort had a baseline BMI filter of at least 35 kg/m², which means the populations are not directly comparable. Conflating the two timelines introduces a systematic interpretive error.

Modern clinical research laboratory with data visualization displays and metabolic analysis equipment
Abstract visualization of pharmaceutical mechanisms and receptor pathway networks

Primary Efficacy Results: Dose-by-Dose Breakdown

At 80 weeks, all three active doses of Retatrutide produced statistically significant and clinically meaningful weight loss compared to placebo. The placebo arm averaged 3.9% body weight reduction. Against that background, the dose-response relationship across the active arms was steep and consistent.

Participants on the 4 mg dose lost an average of 47.2 lb, representing 19.0% of baseline body weight. The 9 mg cohort lost an average of 64.4 lb, or 25.9%. The 12 mg weekly dose, which is the dose most relevant to researchers studying maximum receptor engagement at the GIP, GLP-1, and glucagon receptor, produced a mean reduction of 70.3 lb, translating to 28.3% of baseline body weight. Baseline average weight in the trial was 248.5 lb, with a mean BMI of 40.0 kg/m².

The responder analyses at the 12 mg dose are where the data becomes particularly striking for researchers modeling receptor-mediated metabolic outcomes. At 80 weeks, 45.3% of participants in the 12 mg cohort achieved at least 30% body weight loss. Separately, 65.3% of the 12 mg group reached a BMI below 30 kg/m². These figures do not describe a tail of exceptional responders. They describe what a plurality of participants achieved with sustained triple agonist exposure.

A level of sustained, progressive weight reduction at 30.3% over 104 weeks has never before been observed with a pharmacologic agent at this scale, according to reporting on TRIUMPH-1 data by Pharmacy Times.

One point that deserves emphasis for research design purposes: the dose escalation protocol starting at 2 mg and stepping up every four weeks means participants did not spend 80 weeks at the target dose. The exposure profile is a ramp, not a plateau. Researchers designing in vitro dose-response experiments with Retatrutide should account for this when translating clinical dose data to laboratory concentration protocols.

Pro tip: Do not use the 4 mg endpoint results as a low-efficacy comparator in your receptor modeling work without noting that the 4 mg arm also began at 2 mg and escalated. The clinical exposure trajectory for the 4 mg arm and the 12 mg arm share an early pharmacokinetic overlap that in vitro single-dose experiments will not capture.

Extension Data: What 104 Weeks Tells Researchers

The prespecified blinded extension enrolled 532 participants who had completed 80 weeks on study drug without discontinuation or permanent dose reduction and held a baseline BMI of at least 35 kg/m². Among those originally assigned to the 12 mg dose who remained in the extension, mean body weight loss reached 85.0 lb (30.3%) by week 104. This is the figure that has attracted the most attention from the broader clinical community, and for good reason.

The extension data demonstrates two things that are directly relevant to receptor biology research. First, Retatrutide's effect did not plateau by week 80. The continued downward trajectory from 28.3% at week 80 to 30.3% at week 104 indicates that the compound was still driving weight loss in the later treatment period, at least in this higher-BMI subgroup. Second, there was no meaningful loss of effect observed in the extension cohort, which is a common concern with sustained receptor agonism and potential receptor desensitization.

For researchers focused on incretin receptor biology or downregulation mechanisms, this durability of effect at the glucagon receptor level is a particularly important data point. The mechanism that differentiates Retatrutide from dual GIP/GLP-1 agonists is glucagon receptor agonism driving energy expenditure. The extension data suggests this third arm of the mechanism remains active at clinically relevant timescales that extend well beyond what most preclinical models explore.

Cardiometabolic Secondary Endpoints

Body weight reduction was the primary endpoint, but the cardiometabolic secondary endpoint data from TRIUMPH-1 contains equally relevant information for researchers working on metabolic syndrome, adipose tissue biology, or vascular risk mechanisms. In the 12 mg cohort at 80 weeks, mean waist circumference reduced by 24.1 cm. Favorable changes were observed in non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein (hs-CRP).

The hs-CRP reduction is notable. It suggests a systemic anti-inflammatory signal that extends beyond mechanical weight loss. Whether this reflects a direct receptor-mediated anti-inflammatory pathway or is entirely secondary to adiposity reduction remains an active research question. Labs studying the inflammatory biology of adipose tissue and the role of GLP-1 and glucagon receptors in immune cell function will find this secondary data set worth interrogating in parallel with the weight endpoint data.

Clinical researcher workspace with phase 3 trial documentation and metabolic study materials

The improvements in non-HDL cholesterol and triglycerides are consistent with the broader literature on GLP-1 receptor agonism but may be amplified here by glucagon receptor activity's effect on hepatic lipid metabolism. Glucagon drives hepatic fat oxidation, and reduced hepatic lipid availability would predictably affect circulating lipoprotein profiles. Researchers designing experiments to probe this hepatic mechanism will find TRIUMPH-1's secondary endpoints useful for calibrating what physiologically meaningful effect sizes look like at the clinical scale.

Safety Profile and Adverse Event Data

The adverse event profile from TRIUMPH-1 is consistent with what the incretin-class literature has established, but the dose-dependent graduation across the three active arms provides granular data that preclinical researchers should note. Nausea was reported in 28.6%, 38.4%, and 42.4% of the 4 mg, 9 mg, and 12 mg groups respectively, compared to 14.8% in the placebo arm. Diarrhea occurred in 25.2%, 34.1%, and 32.0% versus 13.5% for placebo. Vomiting was reported in 10.6%, 22.8%, and 25.3% versus 4.8%.

One adverse event that stands out for its mechanistic interest is dysesthesia, reported in 5.1%, 12.3%, and 12.5% of the 4 mg, 9 mg, and 12 mg arms respectively, versus 0.9% in placebo. The dysesthesia events were generally described as mild, and most participants continued treatment. This signal has no clear parallel in the established GLP-1 receptor agonist literature, which points toward the glucagon or GIP receptor contribution as a candidate mechanism worth investigating in sensory neurobiology models.

Discontinuation rates due to adverse events were 4.1%, 6.9%, and 11.3% for the 4 mg, 9 mg, and 12 mg groups respectively, with the placebo arm at 4.9%. The 11.3% discontinuation rate at the highest dose is higher than what the clinical community has observed with approved GLP-1 receptor agonists at their standard doses, and this tolerance profile is a meaningful variable for any translational research model that attempts to predict real-world receptor engagement duration.

The Mechanism Behind the Numbers: Triple Agonism

Retatrutide (LY3437943) is a single molecule that activates three hormone receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon. Understanding how this triple mechanism produces results that are quantitatively distinct from dual GIP/GLP-1 agonism requires appreciating what each receptor contributes independently.

GLP-1 receptor agonism suppresses appetite via central and peripheral signaling, slows gastric emptying, and drives incretin-mediated insulin secretion. GIP receptor agonism adds incretin amplification and has been shown to potentiate GLP-1 effects at the central level. Neither of these mechanisms, alone or in combination, explains the energy expenditure component that makes the TRIUMPH-1 efficacy numbers different in character from what tirzepatide produced at equivalent timepoints.

Glucagon receptor agonism is the distinguishing variable. It directly increases energy expenditure and drives hepatic fat oxidation in ways that GLP-1 and GIP engagement alone cannot replicate. The result is a compound that suppresses caloric intake through two complementary incretin pathways while simultaneously increasing the rate at which stored energy is consumed. This dual-mechanism approach to energy balance is why researchers studying obesity pharmacology view Retatrutide not as an incremental improvement over tirzepatide but as a mechanistically distinct compound requiring its own experimental models.

For laboratory researchers at Pepura Labs' client institutions working with research-grade Retatrutide compounds, this mechanistic complexity has direct practical implications. In vitro experiments designed to characterize receptor binding affinity or downstream signaling at a single receptor need to be explicitly scoped as single-receptor experiments. Any interpretation of Retatrutide's effects as a whole-molecule phenomenon requires experimental systems that can engage all three receptor pathways simultaneously or that can quantify their individual contributions with appropriate controls.

How TRIUMPH-1 Stacks Up: A Comparison of Incretin-Class Phase 3 Data

Researchers who need to position TRIUMPH-1 findings within the broader incretin pharmacology literature will find it useful to compare the headline efficacy and safety data points across the most relevant Phase 3 trials. The table below draws on published Phase 3 data for Semaglutide (STEP-1), Tirzepatide (SURMOUNT-1), and Retatrutide (TRIUMPH-1). All figures are from the highest approved or tested once-weekly doses at the primary endpoint timepoint.

Compound (Highest Dose Tested) Mean Body Weight Loss at Primary Endpoint Key Mechanistic Differentiator
Semaglutide 2.4 mg weekly (STEP-1, 68 weeks) Approximately 15% (placebo-adjusted) GLP-1 receptor agonism only
Tirzepatide 15 mg weekly (SURMOUNT-1, 72 weeks) Approximately 21% mean body weight reduction Dual GIP + GLP-1 receptor agonism
Retatrutide 12 mg weekly (TRIUMPH-1, 80 weeks) 28.3% mean body weight reduction (70.3 lb) Triple GIP + GLP-1 + glucagon receptor agonism

The progression is not linear. Each additional receptor target contributes non-additive effects that appear to compound the overall metabolic outcome. This pattern has direct relevance for researchers designing combination-receptor studies: the data suggests that glucagon receptor co-agonism at physiologically relevant concentrations produces effects that are more than the arithmetic sum of its individual receptor contributions. Designing experiments that test this non-additivity is a meaningful next step for any lab working in this space.

Research Implications for In Vitro and Preclinical Work

TRIUMPH-1's data set creates both new research questions and immediate practical demand. For institutions conducting in vitro receptor pharmacology, the most pressing need following these results is for high-purity, independently verified Retatrutide reference material. Work designed to characterize receptor binding kinetics, downstream cAMP signaling at the glucagon receptor, or comparative selectivity profiles against tirzepatide demands compound purity above 99% with batch-traceable documentation. Anything less introduces unquantifiable noise into mechanistic conclusions.

Research groups at Canadian institutions have particular access advantages here. Pepura Labs supplies research-grade Retatrutide at 99%+ purity, independently verified by Canadian laboratories with full Chain of Custody documentation and batch traceability. For researchers who need to cite compound provenance in publication materials or grant applications, that documentation chain is not a convenience. It is part of the experimental record. Rapid Xpresspost delivery across Canada means that access timelines do not create bottlenecks in research schedules following major data releases like TRIUMPH-1.

The basket trial design of TRIUMPH-1 also opens specific in vitro research directions. The OSA basket, measuring change in Apnea-Hypopnea Index, points toward neuromuscular and brainstem receptor biology that is underexplored in the triple agonist context. The knee OA basket's pain endpoint data, combined with the weight loss effect, raises questions about whether the analgesic benefit is mediated purely through mechanical load reduction or involves direct receptor activity in joint tissue. These are tractable in vitro questions that the TRIUMPH-1 clinical structure has now made scientifically relevant to pursue.

A common mistake in translating Phase 3 clinical data to in vitro work is to design experiments at concentrations calibrated to peak plasma levels from clinical dosing. The stepped escalation protocol in TRIUMPH-1, starting at 2 mg and escalating every four weeks, means participants experienced a wide range of plasma concentrations over the treatment period. Preclinical and in vitro models that want to replicate the clinical exposure profile need to design concentration-time experiments, not single-concentration assays, to produce results that are meaningfully comparable to the TRIUMPH-1 human data.

On regulatory context: as of the time of this writing, Retatrutide remains an investigational compound. A regulatory submission is anticipated in 2026, but no approval has been granted. Researchers supplying or using Retatrutide must ensure its use is clearly scoped to in vitro research applications with appropriate documentation. This applies equally to institutions across Canada and internationally.

Frequently Asked Questions

What was the primary endpoint of the TRIUMPH-1 clinical trial?

The primary endpoint was percent change in body weight from baseline at 80 weeks. All three active doses of Retatrutide, 4 mg, 9 mg, and 12 mg once weekly, met the primary and key secondary endpoints. The 12 mg dose produced a mean reduction of 28.3% (70.3 lb) from a baseline average of 248.5 lb.

How many participants were enrolled in TRIUMPH-1?

The TRIUMPH-1 master trial for obesity enrolled 2,339 participants who were randomized to receive Retatrutide 4 mg, 9 mg, 12 mg, or placebo. All participants began at 2 mg once weekly and escalated the dose every four weeks until reaching the target dose.

What is a basket trial and why was it used in TRIUMPH-1?

A basket trial evaluates a single drug across multiple disease states or patient subgroups sharing a common feature, in this case obesity as the underlying condition. TRIUMPH-1's basket design nested two sub-trials under the obesity master trial: one for moderate-to-severe obstructive sleep apnea and one for knee osteoarthritis pain. Each basket had independent endpoints and statistical controls. This was the first application of a basket trial design in the cardiometabolic therapeutic space.

What does the 104-week extension data show, and who does it apply to?

The prespecified extension enrolled 532 participants who completed 80 weeks on study drug without discontinuation or dose reduction, had a baseline BMI of at least 35 kg/m², and maintained a BMI above 22 at week 80. Among those originally assigned to 12 mg, mean body weight loss reached 85.0 lb (30.3%) by week 104. This cohort is a filtered subset of the 12 mg arm and cannot be compared directly to the primary 80-week endpoint population.

What adverse events were most frequently observed in TRIUMPH-1?

The most common adverse events were gastrointestinal: nausea (up to 42.4% at 12 mg vs. 14.8% for placebo), diarrhea (32.0% vs. 13.5%), constipation (26.1% vs. 10.9%), and vomiting (25.3% vs. 4.8%). Dysesthesia was observed in 12.5% of the 12 mg group versus 0.9% of placebo. Discontinuation rates due to adverse events were 4.1%, 6.9%, and 11.3% for the 4, 9, and 12 mg doses respectively, compared to 4.9% in placebo.

Why does the glucagon receptor component matter for in vitro research design?

The glucagon receptor is what mechanistically distinguishes Retatrutide from dual GIP/GLP-1 agonists. It directly increases energy expenditure and drives hepatic fat oxidation in ways that incretin receptor agonism alone cannot produce. In vitro experiments that ignore the glucagon receptor arm and characterize Retatrutide's effects at only one or two of its three target receptors will produce results that do not represent the compound's full mechanistic profile. Experimental designs need to account for all three receptor pathways, either through multi-receptor assay systems or by separately characterizing each receptor's contribution with appropriate controls.

Is Retatrutide currently approved for clinical use?

No. As of the publication of TRIUMPH-1 topline results in May 2026, Retatrutide remains an investigational compound. A regulatory submission is anticipated in 2026, but no approval by the FDA or Health Canada has been granted. Access to Retatrutide outside of clinical trial enrollment is restricted to research-grade supply for in vitro laboratory use, which must be documented accordingly.

If you are working with Retatrutide in a research context, we would like to hear about what experimental directions TRIUMPH-1 has opened up for your lab. Share your questions or early observations in the comments below.

References

← Back to the Research Library